Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DPP4 | P27487 | 1/20 | 0.40 |
| ▸ | POLB | P06746 | 1/20 | 0.37 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
| ▸ | SIGMAR1 | Q99720 | 7/20 | 0.37 |
| ▸ | HRH4 | Q9H3N8 | 3/20 | 0.36 |
| ▸ | SLC6A5 | Q9Y345 | 1/20 | 0.36 |
| ▸ | SLC18A3 | Q16572 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13874789 | 1.00 | DPP4 (0.40) | DPP4POLBHSD17B10MEN1KMT2A | |
| SCHEMBL12568620 | 1.00 | DPP4 (0.40) | DPP4POLBHSD17B10MEN1KMT2A | |
| SCHEMBL724375 | 0.98 | DPP4 (0.38) | DPP4SIGMAR1HRH4 | |
| SCHEMBL1999934 | 0.98 | DPP4 (0.38) | DPP4SIGMAR1HRH4 | |
| SCHEMBL725303 | 0.98 | DPP4 (0.38) | DPP4SIGMAR1HRH4 | |
| SCHEMBL3637362 | 0.94 | HRH3 (0.36) | DPP4SIGMAR1HRH4 | |
| SCHEMBL12568614 | 0.90 | SIGMAR1 (0.40) | DPP4POLBHSD17B10MEN1KMT2A | |
| SCHEMBL9927934 | 0.90 | SIGMAR1 (0.40) | DPP4POLBHSD17B10MEN1KMT2A | |
| SCHEMBL21386066 | 0.89 | HRH4 (0.34) | HRH4 | |
| SCHEMBL9927923 | 0.88 | SIGMAR1 (0.37) | POLBHSD17B10MEN1KMT2ASIGMAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 36 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3680237-A1 | PROCESS FOR PREPARING SUBSTITUTED 2,3-DIHYDRO-1H-INDEN-1-ONE RETINOIC ACID-RELATED ORPHAN NUCLEAR RECEPTOR ANTAGONISTS FOR TREATING MULTIPLE SCLEROSIS | Arrien Pharmaceuticals LLC (US) | 2020-07-15 | — | — | EP | disclosed |
| US-10682358-B2 | Substituted 2, 3-dihydro-1H-inden-1-one retinoic acid-related orphan nuclear receptor antagonists for treating multiple sclerosis | ARRIEN PHARMACEUTICALS LLC (US) | 2020-06-16 | — | — | US | disclosed |
| EP-3044223-B1 | 2,3-DIHYDRO-1H-INDEN-1-ONE DERIVATIVES AS RETINOIC ACID-RELATED ORPHAN RECEPTOR GAMMA (ROR GAMMA) ANTAGONISTS FOR TREATING MULTIPLE SCLEROSIS | ARRIEN PHARMACEUTICALS LLC (US) | 2020-04-01 | — | — | EP | disclosed |
| US-20190209574-A1 | SUBSTITUTED 2, 3-DIHYDRO-1H-INDEN-1-ONE RETINOIC ACID-RELATED ORPHAN NUCLEAR RECEPTOR ANTAGONISTS FOR TREATING MULTIPLE SCLEROSIS | ARRIEN PHARMACEUTICALS LLC (US) | 2019-07-11 | — | — | US | disclosed |
| US-9669028-B2 | Substituted 5-(pyrazin-2-yl)-1H-pyrazolo [3, 4-B] pyridine and pyrazolo [3, 4-B] pyridine derivatives as protein kinase inhibitors | ARRIEN PHARMACEUTICALS LLC (US) | 2017-06-06 | — | — | US | disclosed |
| US-20160213676-A1 | Substituted 2,3-dihydro-1H-inden-1-one Retinoic acid-related orphan nuclear receptor Antagonists for Treating Multiple Sclerosis | XENTHERA, INC. | 2016-07-28 | — | — | US | disclosed |
| US-20160213627-A1 | Substituted 2,3-dihydro-1H-inden-1-one Retinoic acid-related orphan nuclear receptor Antagonists for Treating Multiple Sclerosis | XENTHERA, INC. | 2016-07-28 | — | — | US | disclosed |
| US-9359315-B2 | Substituted 2,3-dihydro-1H-inden-1-one retinoic acid-related orphan nuclear receptor antagonists for treating multiple sclerosis | ARRIEN PHARMACEUTICALS LLC (US) | 2016-06-07 | — | — | US | disclosed |
| US-20160060261-A1 | SUBSTITUTED 5-(PYRAZIN-2-YL)-1H-PYRAZOLO [3, 4-B] PYRIDINE AND PYRAZOLO [3, 4-B] PYRIDINE DERIVATIVES AS PROTEIN KINASE INHIBITORS | ARRIEN PHARMACEUTICALS LLC | 2016-03-03 | — | — | US | disclosed |
| US-9187473-B2 | Substituted 5-(pyrazin-2-yl)-1H-pyrazolo [3, 4-b] pyridine and pyrazolo [3, 4-b] pyridine derivatives as protein kinase inhibitors | ARRIEN PHARMACEUTICALS LLC (US) | 2015-11-17 | — | — | US | disclosed |
| US-4282244-A | ANTIEMETICS | A. H. ROBINS COMPANY, INC. (US) | 1981-08-04 | — | — | US | disclosed |
| US-4282243-A | ANTICATALEPTIC AGENTS | A. H. ROBINS COMPANY, INC. (US) | 1981-08-04 | — | — | US | disclosed |
| US-4279822-A | ANTIEMETICS | A. H. ROBINS COMPANY, INC. (US) | 1981-07-21 | — | — | US | disclosed |
| US-4087428-A | ANTIEMETICS | A. H. ROBINS COMPANY, INC. (US) | 1978-05-02 | — | — | US | disclosed |
| US-4073796-A | ANTIEMETIC | A. H. ROBINS COMPANY, INC. (US) | 1978-02-14 | — | — | US | disclosed |
| US-4039678-A | N-(SUBSTITUTED-3-PYRROLIDINYL)-1-NAPHTHALENE CARBOXAMIDES | A. H. ROBINS COMPANY, INCORPORATED (US) | 1977-08-02 | — | — | US | disclosed |
| US-4002757-A | ANTIEMETIC AGENTS | A. H. ROBINS COMPANY, INCORPORATED (US) | 1977-01-11 | — | — | US | disclosed |
| US-3966957-A | Method for controlling emesis with N-(1-substituted-3-pyrrolidinyl)benzamides and thiobenzamides | A. H. ROBINS COMPANY, INCORPORATED (US) | 1976-06-29 | — | — | US | disclosed |
| US-3963745-A | Method for controlling emesis with N-(1-substituted-3-pyrrolidinyl)benzamides and thiobenzamides | A. H. ROBINS COMPANY, INCORPORATED (US) | 1976-06-15 | — | — | US | disclosed |
| US-3954729-A | FROM A SECONDARY AMINE, CARBONYL SULFIDE, AND AN ALKYL HALIDE | IHARA CHEMICAL INDUSTRY CO., LTD. (JA) | 1976-05-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10682358-B2 | Substituted 2, 3-dihydro-1H-inden-1-one retinoic acid-related orphan nuclear receptor antagonists for treating multiple sclerosis | RORA, RORB, RORC | DPP4 961/4885POLB 2962/4885HSD17B10 439/4885 |
| US-20160060261-A1 | SUBSTITUTED 5-(PYRAZIN-2-YL)-1H-PYRAZOLO [3, 4-B] PYRIDINE AND PYRAZOLO [3, 4-B] PYRIDINE DERIVATIVES AS PROTEIN KINASE INHIBITORS | MAP3K9, MAP3K19, MAP4K2 | DPP4 2523/4885POLB 885/4885HSD17B10 3723/4885 |
| US-20160213627-A1 | Substituted 2,3-dihydro-1H-inden-1-one Retinoic acid-related orphan nuclear receptor Antagonists for Treating Multiple Sclerosis | RORA, RORB, RORC | DPP4 961/4885POLB 2962/4885HSD17B10 439/4885 |
| US-20190209574-A1 | SUBSTITUTED 2, 3-DIHYDRO-1H-INDEN-1-ONE RETINOIC ACID-RELATED ORPHAN NUCLEAR RECEPTOR ANTAGONISTS FOR TREATING MULTIPLE SCLEROSIS | RORA, RORB, RORC | DPP4 961/4885POLB 2962/4885HSD17B10 439/4885 |
| US-20160213676-A1 | Substituted 2,3-dihydro-1H-inden-1-one Retinoic acid-related orphan nuclear receptor Antagonists for Treating Multiple Sclerosis | RORA, RORB, RORC | DPP4 961/4885POLB 2962/4885HSD17B10 439/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.